Long-Term Noninvasive Ventilation in the Geneva Lake Area: Indications, Prevalence, and Modalities.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
07 2020
Historique:
received: 22 11 2019
revised: 11 01 2020
accepted: 03 02 2020
pubmed: 4 4 2020
medline: 22 5 2021
entrez: 4 4 2020
Statut: ppublish

Résumé

Noninvasive ventilation (NIV) is standard of care for chronic hypercapnic respiratory failure, but indications, devices, and ventilatory modes are in constant evolution. To describe changes in prevalence and indications for NIV over a 15-year period; to provide a comprehensive report of characteristics of the population treated (age, comorbidities, and anthropometric data), mode of implementation and follow-up, devices, modes and settings used, physiological data, compliance, and data from ventilator software. Cross-sectional observational study designed to include all subjects under NIV followed by all structures involved in NIV in the Cantons of Geneva and Vaud (1,288,378 inhabitants). A total of 489 patients under NIV were included. Prevalence increased 2.5-fold since 2000 reaching 38 per 100,000 inhabitants. Median age was 71 years, with 31% being > 75 years of age. Patients had been under NIV for a median of 39 months and had an average of 3 ± 1.8 comorbidities; 55% were obese. COPD (including overlap syndrome) was the most important patient group, followed by obesity hypoventilation syndrome (OHS) (26%). Daytime Paco Use of NIV is increasing rapidly in this area, and the population treated is aging, comorbid, and frequently obese. COPD is presently the leading indication followed by OHS. ClinicalTrials.gov; No.: NCT04054570; URL: www.clinicaltrials.gov.

Sections du résumé

BACKGROUND
Noninvasive ventilation (NIV) is standard of care for chronic hypercapnic respiratory failure, but indications, devices, and ventilatory modes are in constant evolution.
RESEARCH QUESTION
To describe changes in prevalence and indications for NIV over a 15-year period; to provide a comprehensive report of characteristics of the population treated (age, comorbidities, and anthropometric data), mode of implementation and follow-up, devices, modes and settings used, physiological data, compliance, and data from ventilator software.
STUDY DESIGN AND METHODS
Cross-sectional observational study designed to include all subjects under NIV followed by all structures involved in NIV in the Cantons of Geneva and Vaud (1,288,378 inhabitants).
RESULTS
A total of 489 patients under NIV were included. Prevalence increased 2.5-fold since 2000 reaching 38 per 100,000 inhabitants. Median age was 71 years, with 31% being > 75 years of age. Patients had been under NIV for a median of 39 months and had an average of 3 ± 1.8 comorbidities; 55% were obese. COPD (including overlap syndrome) was the most important patient group, followed by obesity hypoventilation syndrome (OHS) (26%). Daytime Paco
INTERPRETATION
Use of NIV is increasing rapidly in this area, and the population treated is aging, comorbid, and frequently obese. COPD is presently the leading indication followed by OHS.
TRIAL REGISTRY
ClinicalTrials.gov; No.: NCT04054570; URL: www.clinicaltrials.gov.

Identifiants

pubmed: 32243941
pii: S0012-3692(20)30551-1
doi: 10.1016/j.chest.2020.02.064
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04054570']

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

279-291

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Chloé Cantero (C)

Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland.

Dan Adler (D)

Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Patrick Pasquina (P)

Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland.

Christophe Uldry (C)

Division of Pulmonary Diseases and Pulmonary Rehabilitation Center, Rolle Hospital Rolle, Vaud, Switzerland.

Bernard Egger (B)

Division of Pulmonary Diseases and Pulmonary Rehabilitation Center, Rolle Hospital Rolle, Vaud, Switzerland.

Maura Prella (M)

Division of Pulmonary Diseases, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Alain B Younossian (AB)

Division of Pulmonary Diseases and Intensive Care, La Tour Hospital, Meyrin, Geneva, Switzerland.

Paola M Soccal (PM)

Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Jean-Louis Pépin (JL)

HP2 laboratory, Inserm U1042 unit, University Grenoble Alps, Grenoble, France; EFCR laboratory, Thorax and vessels, Grenoble Alps University Hospital, Grenoble, France.

Jean-Paul Janssens (JP)

Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland. Electronic address: jean-paul.janssens@hcuge.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH